David Chacko
Retina Specialist · Wichita, KSNPI 1922167303
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,475 of the $8,315 with a category attached, or 65.8%. Genentech USA, Inc. accounts for 86.0% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $7,193, more than ten times the $79 reported in 2019.
Across 70 payments — averaging $118.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$7K
- ANI Pharmaceuticals, Inc.$468
- Astellas Pharma US Inc$121
- Apellis Pharmaceuticals, Inc.$110
- Alcon$94
- Biogen$81
- plus $289 from 8 others
What the payments were for
- Consulting fees$5,47566%
- Travel & lodging$89911%
- Food & beverage$1,94123%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 24 | $7,153 |
| ANI Pharmaceuticals, Inc. | 19 | $468 |
| Astellas Pharma US Inc | 1 | $121 |
| Apellis Pharmaceuticals, Inc. | 4 | $110 |
| Alcon | 2 | $94 |
| Biogen | 3 | $81 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $52 |
| Novartis | 3 | $48 |
| AbbVie(2 entities) | 3 | $48 |
| Aerie Pharmaceuticals, Inc. | 2 | $38 |
| Mallinckrodt Hospital Products Inc. | 1 | $37 |
| Bausch & Lomb Americas Inc. | 2 | $31 |
| Eyepoint US, Inc. | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few retina specialist providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 371 | $14,771 |
| XiidraLifitegrast | 15 | $10,473 |
| Brimonidine Tartrate | 337 | $5,039 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 610 | $4,180 |
| Latanoprost | 555 | $3,813 |
| Atropine Sulfate | 101 | $3,717 |
| Ofloxacin | 270 | $3,280 |
| Timolol Maleate | 282 | $1,685 |
| Dorzolamide Hcl | 63 | $1,094 |
| MoxifloxacinMoxifloxacin Hcl | 33 | $777 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 33 | $553 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 18 | $221 |
| Furosemide | 27 | $177 |
| Ciprofloxacin Hcl | 12 | $149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $31 | $10,47315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Kansason file to place this against a meaningful peer group, so we don't.
Other retina specialist in Wichita
- Paul WeishaarWichita$17K
- Kumar DallaWichita$14K
- Michael VarenhorstWichita$10K
- Brooke NesmithWichita$6K
- Alan HromasWichita$3K
- Thomas WoltjerWichita$2K
- Charles BeckWichita$298
- Javed SayedLeawood$8K
- Mary ChampionPrairie Village$3K
- Radwan AjlanKansas City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.